OCM
SLDB icon

Osbon Capital Management’s Solid Biosciences SLDB Stock Holding History

Osbon Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-501
Closed -$3.61K – 513
2026
Q1 		$3.61K Hold
501
– – ﹤0.01% 384
2025
Q4 		$2.83K Buy
+501
New +$2.71K ﹤0.01% 297

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osbon Capital Management's SLDB Position: Q2 2026 in Review

Osbon Capital Management sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 501 shares — an estimated $3.61K sold.

Osbon Capital Management first reported a position in SLDB in Q4 2025 and held it in 2 quarters. The position peaked at $3.61K in Q1 2026. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Osbon Capital Management reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
  • Osbon Capital Management sold 501 Solid Biosciences shares in Q2 2026, an estimated $3.61K.
  • Osbon Capital Management first reported a position in Solid Biosciences in Q4 2025 and held it in 2 quarters.
  • Osbon Capital Management's Solid Biosciences position peaked at $3.61K in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.